Last reviewed · How we verify

MediQuest Therapeutics — Portfolio Competitive Intelligence Brief

MediQuest Therapeutics pipeline: 0 marketed, 0 filed, 2 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 5 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Topical AmphiMatrix Topical AmphiMatrix phase 3 Dermatology
Topical organogel with nitroglycerin Topical organogel with nitroglycerin phase 3 Nitrate vasodilator Guanylate cyclase (via nitric oxide) Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Aultman Health Foundation · 1 shared drug class
  2. Bristol-Myers Squibb · 1 shared drug class
  3. GF Strong Rehabilitation Centre · 1 shared drug class
  4. Instituto de Cardiologia de Santa Catarina · 1 shared drug class
  5. Ohio State University · 1 shared drug class
  6. Onze Lieve Vrouwe Gasthuis · 1 shared drug class
  7. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 shared drug class
  8. Recep Tayyip Erdogan University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for MediQuest Therapeutics:

Cite this brief

Drug Landscape (2026). MediQuest Therapeutics — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mediquest-therapeutics. Accessed 2026-05-16.

Related